Recon: AbbVie Boosts 2020 Outlook; Novacyt Seeks Emergency Authorization for Coronavirus Test

• First US attempt at CRISPR gene editing in cancer appears safe (Reuters) (Science Mag) (Science) (Endpoints)
• Scott Gottlieb adds one more high-profile board seat to the post-FDA resume. And it’s another plum assignment (Endpoints) (Press)
• Biotech company Novacyt seeks emergency approval for coronavirus test (Reuters)
• AbbVie boosts 2020 outlook despite competition from generic drugs (Financial Times)
• AbbVie touts Humira defense strategy abroad as a positive sign for forthcoming US battle (Fierce)
• Takeda Beats Rivals' Challenge To Diabetes Drug Patent (Law360-$)
• Chiesi launches new rare disease R&D division in Boston (PMLive) (Fierce) (Press)
• Jury orders Johnson & Johnson to pay $750 million in New Jersey talc case (Reuters)

• China Begins Testing an Antiviral Drug in Coronavirus Patients (NYTimes)
• Mainland China reports 73 new coronavirus deaths on February 6, toll rises to 636 (Reuters)
• A lottery like no other offers up a cutting-edge medicine — with lives on the line (STAT)
• Lonza resuming production as coronavirus spread threatens manufacturers (BioPharmaDive)
• Novo Nordisk investing $117.4M in manufacturing site in Denmark (Fierce)
• Drug Prices ‘Not On The Table’ In UK-US Trade Deal Talks (Pink Sheet-$)
• UK Urged To Fund Rare Disease Treatments Immediately (Pink Sheet-$)
• Pharma companies must adhere to marketing norms during conferences: Indian Govt (Economic Times)

• Just a few hundred prescribers responsible for half of US opioid doses (Reuters)
• Time to Ban Heritable Genome Editing (Harvard Bill of Health)
• Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors (NEJM)
• Drugmaker BioMarin Seeks New CFO Amid Coming Release Of Potentially Costliest Drug In The World (Forbes)
• Weak pipeline? Why, Sanofi execs are suddenly over the moon about their prospects (Endpoints)
• 85% of patients see benefit in clinical trials, but 43% were never given the option to participate, report finds (Pharmafile)
• AAM Announces 2020 Board of Directors (AAM)
• Sonoma Bio Launches With $40M to Take Cell Therapy Beyond Cancer (Xconomy)
• Another Takeda/Shire R&D exec jumps ship as Pharvaris nabs Peng Lu as its new CMO (Fierce)
• Sanofi C-suite explains Regeneron deal 'simplification,' ramping up its pipeline (Fierce)
• Biologics Consortium Plans Collaborative Approach To Rapid Methods Validation (Pink Sheet-$)
• Record levels of VC financing and R&D boom left biopharma companies clamoring for space. How bad is it? (Endpoints)
• From mice to dogs, and someday man: George Church's gene therapy cocktail for aging-related diseases (Endpoints)
• Craig Basson tells us why he leapt from NIBR to Boston Pharma; Ex-BMS Partner CytomX finds new CMO in Allison Hannah (Endpoints)
• Diffusion CSO and co-founder Gainer set to resign next month (Fierce)

• So close, yet so far: Zogenix LGS trial succeeds, but results underwhelm (Endpoints) (Press)
• Elios Therapeutics Presents New Phase IIb Data for Personalized Cancer Vaccine in High-Risk Melanoma Patients at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium (Press)

• GE Healthcare recalls nearly 3,600 anesthesia systems (MassDevice) (FDA)
• Snapshot: How medtech earnings season is shaping up (MedtechDive)
• Longtime Myriad CEO resigns amid another steep earnings miss, guidance cut (MedtechDive)
• Verily, Santen do a JV for ophthalmological devices (MassDevice)
• I was fortunate to get post-23andMe genetic counseling. Everyone should have that option (STAT)
• Life Spine Announces FDA 510(k) of the Steerable PLATEAU® Ti System (Press)

• Dueling It Out with FDA over NCE Exclusivity (FDA Law Blog)
• Burning health care questions for tonight’s Democratic debate (Politico)
• A closer look at Bernie Sanders’ plans to upend pharma and lower drug prices (STAT)
• Patients Stuck With Bills After Insurers Don’t Pay As Promised (KHN)
• Pay-For-Delay Ban Risks 'Endless Litigation,' 9th Circ. Told (Law360-$)
• FDA Begins Crackdown On Illegally Marketed E-Cigarettes (Law360-$)
• A Judge Rules That the FDA’s Cigar Box Warning Label Requirement Is Unconstitutional (Yahoo)
• Bayer Can't Seal Internal Essure Docs, Judge Says (Law360-$)
• Ending four years of legal fight, ARCH-backed synthetic DNA maker settles lawsuit with CEO's former employer (Endpoints)
• FNC Won’t Let Mass Litigation Tourism Be (Drug & Device Law)

• FDA Advisory Committee Calendar

• CJEU Confirms 'Pay For Delay' Settlements Can Break EU Law (Pink Sheet-$)
• EU Regulatory System Attacked Over Quality Of Approvals (Pink Sheet-$)
• Irish patients ‘wait three times longer for medicines’ (PharmaLetter-$)

• Strides to acquire 18 abbreviated new drug applications from Pharmaceutics International, Inc (Economic Times)

• Microbiological quality of medicinal cannabis products (TGA)
• Warning about products claiming to treat or prevent the novel coronavirus (TGA)

• WHO says too early to say coronavirus peaking in China (Reuters)
• WHO warns of global shortage of coronavirus protective equipment (Reuters)
• 'Light a candle': Death of Chinese doctor sparks mourning, anger (Reuters) (NBC) (NYTimes)
• China anti-corruption body to probe 'issues' related to Li Wenliang (Reuters)
• Experts scramble, but new virus vaccine may not come in time (AP)
• Brazil's Bolsonaro signs into law bill on quarantine rules for coronavirus (Reuters)
• Italy denies 'groundless' China assertion on resuming flights (Reuters)
• Singapore lifts virus alert to SARS level, sparking panic buying (Reuters)
• Coronavirus screening leads Royal Caribbean to delay cruise from N.J., 4 taken to hospital (NBC)
• Coronavirus cases on cruise ship marooned off Japan rise to 61 (Reuters)

• Five new measles cases reported in Los Angeles area (The Hill)